PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.43 - 1.45
1.18 - 2.36
880.0K / 1.73M (Avg.)
-18.00 | -0.08
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.06%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-8.23%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-22.68%
Negative EBIT growth while 1097.HK is at 75.44%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-72.83%
Negative operating income growth while 1097.HK is at 45.35%. Joel Greenblatt would press for urgent turnaround measures.
-42.27%
Negative net income growth while 1097.HK stands at 70.15%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-42.34%
Negative EPS growth while 1097.HK is at 70.16%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-42.22%
Negative diluted EPS growth while 1097.HK is at 70.16%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.08%
Share change of 0.08% while 1097.HK is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
0.01%
Diluted share change of 0.01% while 1097.HK is zero. Bruce Berkowitz might see a minor difference that could widen over time.
-100.00%
Dividend reduction while 1097.HK stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-63.88%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-80.46%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
47013.22%
Positive 10Y revenue/share CAGR while 1097.HK is negative. John Neff might see a distinct advantage in product or market expansion over the competitor.
313.21%
Positive 5Y CAGR while 1097.HK is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
30.64%
Positive 3Y CAGR while 1097.HK is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
159.90%
Positive long-term OCF/share growth while 1097.HK is negative. John Neff would see a structural advantage in sustained cash generation.
185.52%
5Y OCF/share CAGR above 1.5x 1097.HK's 40.68%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-62.94%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
603.05%
Net income/share CAGR above 1.5x 1097.HK's 50.69% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
130.57%
5Y net income/share CAGR above 1.5x 1097.HK's 32.42%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-57.34%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
0.64%
Positive growth while 1097.HK is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
16.51%
Positive 5Y equity/share CAGR while 1097.HK is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
7.76%
Positive short-term equity growth while 1097.HK is negative. John Neff sees a strong advantage in near-term net worth buildup.
-100.00%
Cut dividends over 10 years while 1097.HK stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.95%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
180.97%
Asset growth above 1.5x 1097.HK's 2.05%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
-10.30%
We’re deleveraging while 1097.HK stands at 20.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-100.00%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-5.33%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.